DRTS
Alpha Tau Medical Ltd
$15.03
+0.41
(+2.80%)
Mkt Cap
1.36B
Volume
752,110
52W Range
3.43-15.17
Sector
Healthcare
Beta
1.21
EPS (TTM)
-1.04 USD
P/E Ratio
-9.34
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.63M) | (31.75M) | (29.16M) | (33.76M) | (27.27M) | (8.88M) | (8.46M) |
| EPS | -0.53 | -0.45 | -0.42 | -0.53 | -0.40 | -0.13 | -0.13 |
| Free Cash Flow | (32.76M) | (22.02M) | (24.36M) | (24.78M) | (14.74M) | (11.02M) | (8.20M) |
| FCF / Share | -0.41 | -0.31 | -0.35 | -0.39 | -0.22 | -0.16 | -0.12 |
| Operating CF | (26.68M) | (19.78M) | (17.96M) | (23.88M) | (11.81M) | (7.25M) | (6.91M) |
| Total Assets | 106.58M | 86.20M | 107.39M | 120.15M | 42.22M | 52.99M | 31.56M |
| Total Debt | 13.73M | 12.54M | 13.28M | 5.19M | 53.96M | 53.96M | 0 |
| Cash & Equiv | 15.98M | 13.72M | 12.66M | 5.84M | 23.24M | 15.60M | 1.83M |
| Book Value | 77.10M | 62.67M | 84.47M | 105.66M | (34.78M) | (8.43M) | (193,000) |
| Return on Equity | -0.55 | -0.51 | -0.35 | -0.32 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.81M) | (22.94M) | (12.14M) | (11.69M) | (10.11M) | (8.69M) | (9.48M) | (6.92M) | (7.37M) | (7.98M) | (7.37M) | (4.91M) |
| EPS | -0.50 | -0.26 | -0.14 | -0.14 | -0.13 | -0.12 | -0.14 | -0.10 | -0.11 | -0.11 | -0.11 | -0.07 |
| Free Cash Flow | 0 | 0 | (32.76M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FCF / Share | N/A | N/A | -0.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating CF | 0 | 0 | (26.68M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 134.25M | 108.77M | 105.65M | 104.69M | 110.95M | 80.93M | 86.20M | 90.73M | 96.05M | 102.44M | 107.39M | 106.74M |
| Total Debt | 15.15M | 14.34M | 13.73M | 13.50M | 13.31M | 12.29M | 12.54M | 12.56M | 12.56M | 12.94M | 13.28M | 6.05M |
| Cash & Equiv | 22.99M | 8.44M | 12.20M | 3.33M | 11.70M | 5.02M | 13.72M | 5.53M | 2.76M | 7.30M | 12.66M | 82,000 |
| Book Value | 44.05M | 69.35M | 77.10M | 77.58M | 86.62M | 56.33M | 62.67M | 69.40M | 74.02M | 79.07M | 84.47M | 89.85M |
| Return on Equity | -1.04 | -0.33 | -0.16 | -0.15 | -0.12 | -0.15 | -0.15 | -0.10 | -0.10 | -0.10 | -0.09 | -0.05 |
DRTS News
Alpha Tau to Participate in September Investor Conferences
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
New Strong Sell Stocks for July 7th
New Strong Sell Stocks for July 2nd
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet